Aurobindo Pharma is planning to broaden portfolio in the US through accelerated growth in injectable, OTC and higher complexity products. The company is also planning to expand presence into new geographies such as Poland and Czech Republic besides enhancing its position in existing countries such as France, Germany, Netherlands, Spain and the UK.
In next three to four years, the company is aiming to build branded generics presence in its growth markets such as Ukraine, Mexico, Tanzania, Colombia, South Africa, Canada, Brazil and GCC Countries.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
